Young blood transfusion
This article is part of a series on |
Alternative medicine |
---|
Young blood transfusion refers to transfusing blood specifically from a young person into an older one with the intention of creating a health benefit.[1] The scientific community currently views the practice as essentially pseudoscientific, with comparisons to snake oil.[1][2][3] There are also concerns of harm.[3] The U.S. Food and Drug Administration, in 2019, cautioned "consumers against receiving young donor plasma infusions" stating that they are an "unproven treatment".[3]
Research
Experiments beginning in the 1950s in the
A study conducted at UC Berkeley found that when delivered alone, blood from older mice was more inhibitory to the regenerative capacities of younger mice than blood from younger mice was beneficial to older ones, and that the benefit of young blood in older mice was less than had been observed when older mice were subjected to parabiosis.[6][7] Replacing plasma of old mice with saline and albumin from young mice was sufficient to rejuvenate brain, liver, and muscle.[7] A 2020 review of plasma components that change with age identified several candidate anti-aging and pro-aging factors.[8]
In experiments like this, researchers found that some of the parabiosed died quickly (11 out of 69 in one experiment) for reasons the scientists could not explain, but described as possibly some form of
A review of studies on donor age for whole blood transfusions reported that blood from donors under the age of 20 years, when compared to donors aged 20–60 years, resulted in a modestly higher risk of death in the recipients.[9] However, other studies have found no effect of age.[10][11] Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.[12]
Another approach to achieving "younger" blood is to rejuvenate blood-producing
Commercial development
In February 2019 the FDA warned about companies offering young blood transfusions stating:
"simply put, we’re concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies. Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful. There are reports of bad actors charging thousands of dollars for infusions that are unproven and not guided by evidence from adequate and well-controlled trials. The promotion of plasma for these unproven purposes could also discourage patients suffering from serious or intractable illnesses from receiving safe and effective treatments that may be available to them."[3][14]
Ambrosia
A startup company, Ambrosia, has been selling "young blood transfusions" for $8,000 since 2016 under the guise of running a
On February 19, 2019, Ambrosia announced it stopped testing the treatment, responding to concerns from the FDA.[14]
Alkahest
Another company, Alkahest, was founded based on the Stanford rodent studies. As of 2017 it is collaborating with European pharmaceutical company
Maharaj/Faloon trial
Young Blood Institute
An organization called the Young Blood Institute has also run trials; these, however, involved exchange only of blood plasma.[23]
See also
- Bryan Johnson: Tech Billionaire that attempted the practice as part of "Project Blueprint"
References
- ^ a b c d e Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
- ^ a b c d e f g Robbins, Rebecca (March 2, 2018). "Young-Blood Transfusions Are on the Menu at Society Gala". Scientific American. Retrieved 26 May 2018.
- ^ a b c d "Statement from FDA Commissioner Scott Gottlieb, M.D., and Director of FDA's Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., cautioning consumers against receiving young donor plasma infusions that are promoted as unproven treatment for varying conditions". FDA. 19 February 2019. Retrieved 20 February 2019.
- ^ PMID 23489470.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - PMID 25612035.
- PMID 27874859.
- ^ PMID 32474458.
- PMID 33197235.
- PMID 28437543.
- PMID 26702060. Retrieved 30 July 2020.
- S2CID 3604995. Retrieved 30 July 2020.
- PMID 28988603.
- ^ Irving, Michael (2023-02-06). "Arthritis drug mimics "young blood" transfusions to reverse aging in mice". New Atlas. Retrieved 2023-02-06.
- ^ a b Mole, Beth (February 19, 2019). "Blood of the young won't spare rich old people from sadness and death, FDA says". Ars Technica. Archived from the original on February 20, 2019. Retrieved February 20, 2019.
- ^ PMID 28778607.
- ^ a b Haynes, Gavin (21 August 2017). "Ambrosia: the startup harvesting the blood of the young". The Guardian. Retrieved 23 May 2018.
- ^ a b Maxmen, Amy (January 13, 2017). "This startup takes cash from aging adults in exchange for young people's blood". MIT Technology Review. Retrieved May 26, 2018.
- PMID 28953857.
- ^ "Young Donor Plasma Transfusion and Age-Related Biomarkers". ClinicalTrials.gov. 17 June 2016. Retrieved 2 March 2020.
- ^ "The Hippocrates Health Institute: Cancer quackery finally under the spotlight, but will it matter?". Science-Based Medicine. 2015-02-23. Retrieved 2018-06-09.
- ^ Funcheon, Deirdra (2015-05-12). "South Florida Church Pursues Eternal Life Through Cryonics, Inflaming Critics and the IRS". Miami New Times. Retrieved 2018-06-10.
- ^ Almond, Steven (1994-06-08). "They're Gonna Live Forever". Miami New Times. Retrieved 2018-06-09.
- ^ Basu, Tanya; Weill, Kelly (22 February 2019). "FDA Warns: Don't Give These Companies Your 'Young Blood'". The Daily Beast. Retrieved 15 December 2019.
Further reading
- Makin, Simon (21 April 2017). "Fountain of Youth? Young Blood Infusions "Rejuvenate" Old Mice". Scientific American. Retrieved 5 May 2018.